NCT05036200 (PDL) is a NA clinical trial of pulsed dye laser in Telangiectasia, sponsored by University Hospital, Caen.

Who is sponsoring NCT05036200?

NCT05036200 is sponsored by University Hospital, Caen.

What drugs are being tested in NCT05036200?

Interventions in NCT05036200: pulsed dye laser.

What condition does NCT05036200 study?

NCT05036200 studies Telangiectasia.

Is NCT05036200 still recruiting?

NCT05036200 is currently completed. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT05036200: PDL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma

Completed NA Last updated 2 April 2026

What this trial tests

NA trial testing pulsed dye laser in Telangiectasia in 21 participants. Completed in 1 July 2020.

Timeline

1 August 2019

Primary endpoint
1 September 2019

1 July 2020

Quick facts

Lead sponsor	University Hospital, Caen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 August 2019
Primary completion	1 September 2019
Estimated completion	1 July 2020
Sites	1 location across France

Drugs / interventions tested

pulsed dye laser

Conditions studied

Telangiectasia — all drugs for Telangiectasia →

Sponsor

University Hospital, Caen

Who can join

18 and older, any sex, with Telangiectasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-center, prospective, open-label, quasi-experimental, intra-individual comparative study will include a consecutive cohort of 21 patients with diffuse or limited, minimally active scleroderma with 3 to 30 years of evolution. Patients will have 4 sessions of pulsed dye laser 595 nm spaced 8 weeks apart. The final quadruple evaluation by several evaluators will be 2 months after the last session, on the following criteria: evolution of the number of telangiectasia; subjective improvement score (LINKERT scale); impact on quality of life (SKINDEX score); visual analog pain scale (VAS); adverse events (AEs), including discontinuation of treatment due to post-session purpura (AT-PPS); patient satisfaction (yes or no).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of pulsed dye laser

Trials testing the same drug.

NCT03986346 — The Vascularity Changes of Scars With Laser Therapy · NA · completed
NCT01488240 — The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars · NA · recruiting

Other recruiting trials for Telangiectasia

Currently open trials in the same condition.

NCT03646955 — Partial Breast Versus no Irradiation for Women With Early Breast Cancer · NA · recruiting

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05036200 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing